JP6483804B2 - 新規なｈｄｍｘ阻害剤およびガン治療のためのその使用 - Google Patents

新規なｈｄｍｘ阻害剤およびガン治療のためのその使用 Download PDF

Info

Publication number
JP6483804B2
JP6483804B2 JP2017503776A JP2017503776A JP6483804B2 JP 6483804 B2 JP6483804 B2 JP 6483804B2 JP 2017503776 A JP2017503776 A JP 2017503776A JP 2017503776 A JP2017503776 A JP 2017503776A JP 6483804 B2 JP6483804 B2 JP 6483804B2
Authority
JP
Japan
Prior art keywords
hdmx
ctx1
cells
cell
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017503776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516842A (ja
JP2017516842A5 (OSRAM
Inventor
ウォールド，デーヴィッド
アガルワール，ムケシュ
シア，ジチン
カラン，グータム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirx Pharmaceuticals LLC
Original Assignee
Mirx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirx Pharmaceuticals LLC filed Critical Mirx Pharmaceuticals LLC
Publication of JP2017516842A publication Critical patent/JP2017516842A/ja
Publication of JP2017516842A5 publication Critical patent/JP2017516842A5/ja
Application granted granted Critical
Publication of JP6483804B2 publication Critical patent/JP6483804B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/02—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
JP2017503776A 2014-03-31 2015-03-31 新規なｈｄｍｘ阻害剤およびガン治療のためのその使用 Expired - Fee Related JP6483804B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972514P 2014-03-31 2014-03-31
US61/972,514 2014-03-31
PCT/US2015/023462 WO2015153535A1 (en) 2014-03-31 2015-03-31 Novel hdmx inhibitors and their use for cancer treatment

Publications (3)

Publication Number Publication Date
JP2017516842A JP2017516842A (ja) 2017-06-22
JP2017516842A5 JP2017516842A5 (OSRAM) 2018-05-17
JP6483804B2 true JP6483804B2 (ja) 2019-03-13

Family

ID=54241190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017503776A Expired - Fee Related JP6483804B2 (ja) 2014-03-31 2015-03-31 新規なｈｄｍｘ阻害剤およびガン治療のためのその使用

Country Status (5)

Country Link
US (1) US10183912B2 (OSRAM)
EP (1) EP3125891A4 (OSRAM)
JP (1) JP6483804B2 (OSRAM)
CA (1) CA2944462A1 (OSRAM)
WO (1) WO2015153535A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016075333A1 (en) * 2014-11-14 2016-05-19 Vib Vzw Direct and selective inhibition of mdm4 for treatment of cancer
IL255290B2 (en) 2015-04-27 2024-01-01 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Substances that bind to EGF1 and their use in the treatment of inflammatory diseases and tumors
AU2018364990B2 (en) * 2017-11-09 2023-08-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compounds for inhibiting Ly6K and methods of using same
CN119241434A (zh) * 2021-12-25 2025-01-03 珞达生物医药(苏州)有限公司 固有免疫激活药物及其用途
CN114805205A (zh) * 2022-04-27 2022-07-29 郑州大学 一种吖啶类化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA805652B (en) * 1979-09-14 1981-09-30 New Zealand Dev Finance Compounds having antitumour properties
US5939428A (en) * 1996-06-20 1999-08-17 National Health Research Institutes Alkyl N- 3-(acridin-9-yl)amino-5-hydroxymethyl! phenylcarbamates
FI20000480A0 (fi) * 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
US7232663B2 (en) * 2005-07-13 2007-06-19 The University Of Wyoming Assays employing novel substrates for measuring P450-mediated N-dealkylation
WO2008010984A2 (en) * 2006-07-17 2008-01-24 The Trustees Of The University Of Pennsylvania Acridine activation of p53 and uses thereof
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
US20120220537A1 (en) * 2009-11-01 2012-08-30 Ariel-University Research And Development Company Ltd. 9-aminoacridine derivatives, their preparation and uses

Also Published As

Publication number Publication date
US10183912B2 (en) 2019-01-22
EP3125891A4 (en) 2017-08-09
US20170022166A1 (en) 2017-01-26
WO2015153535A1 (en) 2015-10-08
JP2017516842A (ja) 2017-06-22
EP3125891A1 (en) 2017-02-08
CA2944462A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
CN113164495B (zh) E3连接酶的共价靶向
JP6389884B2 (ja) 癌を治療するための方法及び組成物
Sidera et al. HSP90 inhibitors: current development and potential in cancer therapy
JP6483804B2 (ja) 新規なｈｄｍｘ阻害剤およびガン治療のためのその使用
Krishnegowda et al. Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway
JP2020536847A (ja) プログラマブルなポリマー薬物
JP2021510698A (ja) 生物学的に活性な化合物を含むホスホアルキルリボースポリマー
JP2021506788A (ja) 生物学的に活性な化合物を含むイオン性ポリマー
WO2021195279A2 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
AU2019362576B2 (en) Flavagline derivatives for inhibition of KRAS oncogene activation
JP2007532552A (ja) Ｐｔｅｎインヒビター
JP2018062526A (ja) ｍＴＯＲ経路関連疾患を治療するための化合物
Miao et al. A novel harmine derivative, N-(4-(hydroxycarbamoyl) benzyl)-1-(4-methoxyphenyl)-9H-pyrido [3, 4-b] indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects
EP2968379A1 (en) Etoposide and prodrugs thereof for use in targeting cancer stem cells
JP6137703B2 (ja) 癌におけるエピジェネティックな欠陥を修復するためのエフェクタータンパク質相互作用のリプログラミング
JP2022521452A (ja) Ｐｉｎ１活性のモジュレータおよびその使用
AU2017221422A1 (en) MAX binders as Myc modulators and uses thereof
JP2013518906A (ja) 複製タンパク質ａを阻害する物質および方法ならびにその使用
US6566341B1 (en) Derivative of isoindigo, indigo and indirubin for the treatment of cancer
CN114025766A (zh) 用于抑制gapdh的噁噻嗪化合物
CN103113274B (zh) Ras和HDAC双重抑制剂及其制备方法和用途
ES2877809T3 (es) Terapia combinada para enfermedades proliferativas
JP7138975B2 (ja) 新生物障害及び神経性障害の診断、治療及び予防のための組成物及び方法
CA3233398A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
EP4516790A1 (en) Covalent targeting of rhoa for cancer therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190214

R150 Certificate of patent or registration of utility model

Ref document number: 6483804

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees